announced revenues of $59.2 million,
operating income of $15.9 million and
income before an accounting change at
$6.8 million for the third quarter ended
For the first nine months, total revenues
were $181.2 million, operating
income was $45.4 million and income
before accounting change was $18.9
million. Earnings a share grew 27%
compared to the same period in 2002.
Third quarter results were aided by
year-over-year sales increases from
Gold Bond, SelsunBlue, Garlique and
NewPhase. Gains were offset by
declines in topical analgesics, Dexatrim,
pHisoderm and Pamprin.
Net sales of Gold Bond rose 18%, led
by the three new items shipped in the
second quarter and the continuing
strength of the foot care portion of the
business, company executives said.
Domestic net sales of SelsunBlue
Icy Hot sales were flat for the quarter.
Sales of pHisoderm were down 29%
due to comparisons between the yearago
period, when the brand was
relaunched and the Clear Confidence
Clear Swab was introduced.
However, retail sales for pHisoderm
for the 13-week period ended Aug. 23
were down 1%.